IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
SymbolNYSE:IQV
CUSIPN/A
Phone919-998-2000
Debt
Debt-to-Equity Ratio1.21%
Current Ratio1.19%
Quick Ratio1.19%
Price-To-Earnings
Trailing P/E Ratio22.54
Forward P/E Ratio19.72
P/E Growth1.65
Sales & Book Value
Annual Sales$9.74 billion
Price / Sales2.12
Cash Flow$9.9497 per share
Price / Cash9.95
Book Value$40.19 per share
Price / Book2.46
Profitability
EPS (Most Recent Fiscal Year)$4.36
Net Income$1.31 billion
Net Margins13.44%
Return on Equity13.03%
Return on Assets4.65%
Miscellaneous
Employees55,000
Outstanding Shares208,270,000
Iqvia (NYSE:IQV) Frequently Asked Questions
What is Iqvia's stock symbol?
Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."
How were Iqvia's earnings last quarter?
Iqvia Holdings Inc (NYSE:IQV) posted its earnings results on Wednesday, February, 14th. The medical research company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.34 by $0.02. The medical research company had revenue of $2.16 billion for the quarter, compared to analysts' expectations of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. Iqvia's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.09 EPS. View Iqvia's Earnings History.
When is Iqvia's next earnings date?
What guidance has Iqvia issued on next quarter's earnings?
Iqvia updated its FY18 earnings guidance on Wednesday, February, 14th. The company provided EPS guidance of $5.35-5.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.34. The company issued revenue guidance of $8.45-8.65 billion, compared to the consensus revenue estimate of $8.53 billion.Iqvia also updated its Q1 guidance to $1.23-1.30 EPS.
What price target have analysts set for IQV?
17 brokerages have issued 1-year target prices for Iqvia's shares. Their forecasts range from $93.42 to $128.00. On average, they anticipate Iqvia's share price to reach $110.3776 in the next year. View Analyst Ratings for Iqvia.
Who are some of Iqvia's key competitors?
Some companies that are related to Iqvia include Incyte (INCY), ICON (ICLR), Exelixis (EXEL), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Viralytics (VRACY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Senomyx (SNMX).
Who are Iqvia's key executives?
Iqvia's management team includes the folowing people:
- Ari Bousbib, Chairman of the Board, President, Chief Executive Officer (Age 56)
- Michael R. McDonnell, Chief Financial Officer, Executive Vice President (Age 53)
- Kevin C. Knightly, President - Information and Technology Solutions (Age 55)
- W. Richard Staub III, President - Research and Development Solutions (Age 54)
- Erlinger M. Sherbet, Executive Vice President, General Counsel, Secretary (Age 52)
- Dennis B. Gillings Ph.D., Lead Director (Age 72)
- John P. Connaughton, Independent Director (Age 54)
- Jonathan J. Coslet, Independent Director (Age 52)
- John G. Danhakl, Independent Director (Age 60)
- Michael J. Evanisko, Independent Director (Age 67)
Has Iqvia been receiving favorable news coverage?
Media stories about IQV stock have trended somewhat negative this week, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Iqvia earned a media sentiment score of -0.02 on Accern's scale. They also gave press coverage about the medical research company an impact score of 46.14 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Iqvia?
Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iqvia's stock price today?
One share of IQV stock can currently be purchased for approximately $99.00.
How big of a company is Iqvia?
Iqvia has a market capitalization of $20.26 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.
How can I contact Iqvia?
Iqvia's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]
MarketBeat Community Rating for Iqvia (IQV)
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
Iqvia (NYSE:IQV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
18 Wall Street analysts have issued ratings and price targets for Iqvia in the last 12 months. Their average twelve-month price target is $110.3776, suggesting that the stock has a possible upside of 11.49%. The high price target for IQV is $128.00 and the low price target for IQV is $93.42. There are currently 6 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.67 | 2.65 | 2.59 | 2.47 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
10 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $110.3776 | $109.9071 | $107.2763 | $93.6424 |
| Price Target Upside: | 11.49% upside | 9.19% upside | 3.90% upside | 6.22% downside |
Iqvia (NYSE:IQV) Consensus Price Target History
Iqvia (NYSE:IQV) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Iqvia (NYSE:IQV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Iqvia (NYSE IQV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.00%
Institutional Ownership Percentage: 92.58%
Iqvia (NYSE IQV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/18/2018 | Michael J Evanisko | Director | Sell | 815 | $100.00 | $81,500.00 | |  |
| 3/15/2018 | Robert Parks | Insider | Sell | 896 | $105.73 | $94,734.08 | | |
| 3/5/2018 | Michael J Evanisko | Director | Sell | 816 | $100.00 | $81,600.00 | | |
| 2/26/2018 | James H Erlinger III | Insider | Sell | 10,000 | $100.00 | $1,000,000.00 | | |
| 1/17/2018 | James H Erlinger III | Insider | Sell | 10,000 | $99.97 | $999,700.00 | | |
| 12/20/2017 | James H Erlinger III | Insider | Sell | 10,000 | $101.21 | $1,012,100.00 | | |
| 12/1/2017 | Ari Bousbib | Insider | Sell | 46,080 | $101.79 | $4,690,483.20 | | |
| 11/30/2017 | Cpp Investment Board Private H | Major Shareholder | Sell | 7,497,807 | $102.00 | $764,776,314.00 | | |
| 11/30/2017 | John Connaughton | Director | Sell | 1,163,191 | $102.00 | $118,645,482.00 | | |
| 11/6/2017 | Jack M Greenberg | Director | Sell | 33,400 | $108.07 | $3,609,538.00 | | |
| 11/1/2017 | Ari Bousbib | Insider | Sell | 46,080 | $108.14 | $4,983,091.20 | 1,036,839 | |
| 10/18/2017 | James H Erlinger III | Insider | Sell | 10,000 | $100.51 | $1,005,100.00 | 27,340 | |
| 10/2/2017 | Ari Bousbib | Insider | Sell | 46,080 | $94.91 | $4,373,452.80 | 1,036,839 | |
| 9/27/2017 | James H Erlinger III | Insider | Sell | 10,000 | $94.52 | $945,200.00 | 27,340 | |
| 9/19/2017 | Cpp Investment Board Private H | Major Shareholder | Sell | 6,748,026 | $94.87 | $640,185,226.62 | | |
| 9/19/2017 | John Connaughton | Director | Sell | 1,030,429 | $94.87 | $97,756,799.23 | | |
| 9/1/2017 | Ari Bousbib | Insider | Sell | 46,080 | $95.65 | $4,407,552.00 | 1,036,839 | |
| 8/28/2017 | Cpp Investment Board Private H | Major Shareholder | Sell | 5,218,245 | $97.33 | $507,891,785.85 | | |
| 8/28/2017 | Dennis B Ph D Gillings | Director | Sell | 968,023 | $97.33 | $94,217,678.59 | 9,071,839 | |
| 8/25/2017 | Kevin C Knightly | Insider | Sell | 19,339 | $99.51 | $1,924,423.89 | 40,650 | |
| 8/9/2017 | Kevin C Knightly | Insider | Sell | 20,000 | $90.28 | $1,805,600.00 | 46,826 | |
| 8/7/2017 | Ari Bousbib | Insider | Sell | 92,160 | $90.35 | $8,326,656.00 | 1,082,919 | |
| 5/31/2017 | Cpp Investment Board Private H | Major Shareholder | Sell | 7,131,165 | $84.01 | $599,089,171.65 | | |
| 5/31/2017 | Dennis B Ph D Gillings | Director | Sell | 860,000 | $84.01 | $72,248,600.00 | 10,002,230 | |
| 5/30/2017 | John G Danhakl | Director | Sell | 761,143 | $84.01 | $63,943,623.43 | | |
| 5/17/2017 | Jack M Greenberg | Director | Sell | 6,092 | $82.50 | $502,590.00 | 2,930 | |
| 11/21/2016 | Jack M Greenberg | Director | Sell | 2,000 | $79.77 | $159,540.00 | 2,930 | |
| 6/9/2016 | Kevin K Gordon | COO | Sell | 24,000 | $66.41 | $1,593,840.00 | 41,899 | |
| 6/7/2016 | Corp 3I | Major Shareholder | Sell | 2,250,000 | $66.10 | $148,725,000.00 | | |
| 5/12/2016 | Annie H Lo | Director | Buy | 502 | $64.80 | $32,529.60 | 2,062 | |
| 5/10/2016 | Kevin K Gordon | COO | Sell | 24,000 | $67.42 | $1,618,080.00 | 41,899 | |
| 4/12/2016 | Kevin K Gordon | COO | Sell | 24,000 | $69.44 | $1,666,560.00 | 41,899 | |
| 3/22/2016 | Kevin K Gordon | COO | Sell | 3,639 | $65.01 | $236,571.39 | 21,538 | |
| 3/18/2016 | Kevin K Gordon | COO | Sell | 20,361 | $65.01 | $1,323,668.61 | 19,950 | |
| 3/1/2016 | Kevin K. Gordon | COO | Sell | 24,000 | $65.03 | $1,560,720.00 | 41,899 | |
| 9/2/2015 | Charles Edward Williams | SVP | Sell | 5,000 | $72.43 | $362,150.00 | 2,071 | |
| 5/19/2015 | Dennis B Ph D Gillings | Major Shareholder | Sell | 2,503,123 | $64.85 | $162,327,526.55 | | |
| 5/19/2015 | Tpg Advisors V, Inc. | Insider | Sell | 2,251,719 | $64.85 | $146,023,977.15 | | |
| 3/25/2015 | Michael J Evanisko | Director | Sell | 2,500 | $67.10 | $167,750.00 | | |
| 2/2/2015 | Kevin K Gordon | CFO | Sell | 25,000 | $60.19 | $1,504,750.00 | | |
| 1/7/2015 | Michael J Evanisko | Director | Sell | 2,500 | $57.86 | $144,650.00 | | |
| 1/2/2015 | Kevin K Gordon | CFO | Sell | 25,000 | $59.16 | $1,479,000.00 | | |
| 12/11/2014 | Jack M Greenberg | Director | Sell | 23,508 | $57.29 | $1,346,773.32 | | |
| 12/1/2014 | Kevin K Gordon | CFO | Sell | 25,000 | $56.77 | $1,419,250.00 | | |
| 11/10/2014 | Dennis B Ph D Gillings | Major Shareholder | Sell | 3,566,187 | $58.09 | $207,159,802.83 | | |
| 11/7/2014 | Michael J Evanisko | Director | Sell | 2,500 | $57.50 | $143,750.00 | | |
| 11/3/2014 | Kevin K Gordon | CFO | Sell | 25,000 | $59.00 | $1,475,000.00 | | |
| 7/2/2014 | Michael J Evanisko | Director | Sell | 5,000 | $54.00 | $270,000.00 | | |
| 5/27/2014 | Tpg Advisors Iii, Inc. | Major Shareholder | Sell | 3,287,209 | $50.23 | $165,116,508.07 | | |
| 3/26/2014 | Christopher Gordon | Director | Sell | 570,682 | $50.31 | $28,711,011.42 | | |
| 3/26/2014 | Dennis Ph Gillings | major shareholder | Sell | 570,681 | $50.31 | $28,710,961.11 | 16,609,827 | |
| 3/18/2014 | Mireille Phd Gillings | Director | Sell | 3,304,542 | $50.31 | $166,251,508.02 | | |
| 3/18/2014 | Tpg Advisors Iii, Inc. | major shareholder | Sell | 3,564,119 | $50.31 | $179,310,826.89 | | |
| 1/17/2014 | Derek Winstanly | VP | Sell | 60,000 | $50.00 | $3,000,000.00 | 229,500 | |
| 1/16/2014 | Michael Evanisko | Director | Sell | 5,000 | $50.00 | $250,000.00 | 15,400 | |
| 1/10/2014 | Derek Winstanly | VP | Sell | 60,000 | $48.00 | $2,880,000.00 | 229,500 | |
| 12/20/2013 | Derek Winstanly | VP | Sell | 60,000 | $46.00 | $2,760,000.00 | 229,500 | |
| 12/10/2013 | Derek Winstanly | VP | Sell | 60,000 | $44.00 | $2,640,000.00 | 229,500 | |
| 11/20/2013 | Michael Evanisko | Director | Sell | 8,000 | $43.00 | $344,000.00 | 20,400 | |
| 11/18/2013 | John Ratliff | COO | Sell | 212,140 | $42.55 | $9,026,557.00 | | |
| 11/18/2013 | Michael Mortimer | VP | Sell | 200,000 | $42.55 | $8,510,000.00 | 25,000 | |
| 5/14/2013 | Group Holdings (Sbs) Advis Tpg | Major Shareholder | Sell | 3,944,899 | $37.80 | $149,117,182.20 | | |
| 5/14/2013 | Mireille Gillings | Director | Sell | 2,257,805 | $37.80 | $85,345,029.00 | | |
(Data available from 1/1/2013 forward)
Iqvia (NYSE IQV) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | EARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi Arabia
finance.yahoo.com - April 21 at 4:41 PM |
 | Insider Selling: Iqvia Holdings Inc (IQV) Director Sells 815 Shares of Stock
www.americanbankingnews.com - April 20 at 7:40 PM |
 | Prescriptions of the drugs that fueled the overdose crisis are dropping around the US
www.businessinsider.com - April 19 at 9:09 AM |
| IQVIA™ Institute for Human Data Science Study: U.S. Prescription Opioid Volume Declined 12 Percent in 2017 – Largest Drop in 25 Years
finance.yahoo.com - April 19 at 9:09 AM |
| Iqvia Holdings Inc (IQV) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 18 at 5:17 PM |
| IQVIA to Announce First-Quarter 2018 Results on May 2, 2018
finance.yahoo.com - April 18 at 4:56 PM |
| Iqvia (IQV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 18 at 7:46 AM |
| $2.44 Billion in Sales Expected for Iqvia Holdings Inc (IQV) This Quarter
www.americanbankingnews.com - April 16 at 1:56 AM |
| Zacks: Analysts Expect Iqvia Holdings Inc (IQV) to Post $1.28 EPS
www.americanbankingnews.com - April 14 at 11:20 PM |
| Reviewing EXACT Sciences (EXAS) and Iqvia (IQV)
www.americanbankingnews.com - April 14 at 5:27 PM |
 | Goldman likes CRO space, sees 17% upside in IQVIA; shares up 2%
seekingalpha.com - April 13 at 4:43 PM |
| Goldman Sachs Upgrades Iqvia (IQV) to "Buy"
www.americanbankingnews.com - April 13 at 10:37 AM |
| Financial Review: Iqvia (IQV) & Exelixis (EXEL)
www.americanbankingnews.com - April 12 at 5:27 PM |
 | Dennis Gillings retires from Iqvia's board of directors
www.bizjournals.com - April 12 at 4:43 PM |
| Does IQVIA Holdings Inc’s (NYSE:IQV) PE Ratio Signal A Buying Opportunity?
finance.yahoo.com - April 12 at 4:43 PM |
| Dennis Gillings retires from Iqvia’s board of directors
finance.yahoo.com - April 12 at 4:43 PM |
| Argus Raises Iqvia (IQV) Price Target to $112.00
www.americanbankingnews.com - April 9 at 11:02 AM |
| Zacks Investment Research Lowers Iqvia (IQV) to Hold
www.americanbankingnews.com - April 5 at 4:38 PM |
| Iqvia (IQV) Price Target Raised to $110.00 at Jefferies Group
www.americanbankingnews.com - April 4 at 1:20 PM |
| Iqvia (IQV) Downgraded by ValuEngine
www.americanbankingnews.com - April 3 at 11:31 PM |
| Zacks Investment Research Upgrades Iqvia (IQV) to Buy
www.americanbankingnews.com - April 3 at 9:19 PM |
| From BDSI to Red Hat: The Triangle's top inside stock sales of 1Q2018
finance.yahoo.com - April 3 at 4:43 PM |
| Iqvia's (IQV) "Outperform" Rating Reaffirmed at Credit Suisse Group
www.americanbankingnews.com - April 2 at 8:05 PM |
| Iqvia (IQV) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 9:48 PM |
 | We took 65% more antibiotics in 2015 than we did in 2000
www.msn.com - March 27 at 4:34 PM |
| Iqvia (IQV) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 1:17 PM |
| Iqvia (IQV) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 25 at 11:05 AM |
| Iqvia Holdings Inc (IQV) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 24 at 5:42 PM |
| Iqvia (IQV) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 23 at 9:02 PM |
 | Active-Investors: Free Research Report as IQVIA's Quarterly Revenues Grew 10.7%; Turned Profitable Y-O-Y
www.finanznachrichten.de - March 23 at 9:09 AM |
| Free Research Report as IQVIA’s Quarterly Revenues Grew 10.7%; Turned Profitable Y-O-Y
finance.yahoo.com - March 23 at 9:09 AM |
| Robert Parks Sells 896 Shares of Iqvia Holdings Inc (IQV) Stock
www.americanbankingnews.com - March 16 at 8:36 PM |
| IQVIA Establishes Alliance with MuleSoft to Deliver Innovative Integration Technology to Life Sciences Companies
finance.yahoo.com - March 15 at 9:03 AM |
| Tillerson is Done...and so is the NASDAQ's Winning Streak
finance.yahoo.com - March 14 at 6:02 PM |
| Tillerson is Done...and so is the NASDAQ's Winning Streak
finance.yahoo.com - March 14 at 10:06 AM |
| IQVIA Forms Alliance with Box to Provide Revolutionary, Cloud-Based Content Management Solutions to the Life Sciences and Healthcare Industries
finance.yahoo.com - March 14 at 10:06 AM |
| IQVIA Institute for Human Data Science Study: 10 Predictions for Innovation, Spending Drivers and Societal Value of Medicines that Will Transform Global Healthcare in 2018 and Beyond
finance.yahoo.com - March 13 at 9:27 AM |
| Iqvia Holdings Inc (IQV) Expected to Post Earnings of $1.28 Per Share
www.americanbankingnews.com - March 11 at 6:39 PM |
| Iqvia (IQV) Raised to "Buy" at SunTrust Banks
www.americanbankingnews.com - March 11 at 1:48 PM |
| Biohaven Pharmaceutical (BHVN) versus Iqvia (IQV) Head-To-Head Review
www.americanbankingnews.com - March 11 at 6:02 AM |
| Iqvia Holdings Inc (IQV) Director Sells $81,600.00 in Stock
www.americanbankingnews.com - March 7 at 7:30 PM |
 | Technical Perspectives on Medical Research Stocks -- Bruker, DexCom, Invitae, and IQVIA - PR Newswire (press release)
www.prnewswire.com - March 7 at 9:19 AM |
| Stocks Fight Their Way Forward Amid Tariff Concerns
finance.yahoo.com - March 7 at 9:19 AM |
| Steve Mandel Expands Reach in Health Care Space With Exact Sciences
finance.yahoo.com - March 6 at 5:00 PM |
| Standard Life Aberdeen plc Invests $2.65 Million in Iqvia Holdings Inc (IQV) Stock
www.americanbankingnews.com - March 5 at 4:03 PM |
| Alliancebernstein L.P. Takes Position in Iqvia Holdings Inc (IQV)
www.americanbankingnews.com - March 5 at 4:08 AM |
| American International Group Inc. Buys New Holdings in Iqvia Holdings Inc (IQV)
www.americanbankingnews.com - March 4 at 4:24 AM |
| Tiger Eye Capital LLC Invests $21.23 Million in Iqvia Holdings Inc (IQV) Stock
www.americanbankingnews.com - March 2 at 9:29 PM |
| Lazard Asset Management LLC Buys New Position in Iqvia Holdings Inc (IQV)
www.americanbankingnews.com - March 2 at 2:21 PM |
| 15,699 Shares in Iqvia Holdings Inc (IQV) Purchased by First Republic Investment Management Inc.
www.americanbankingnews.com - March 2 at 11:48 AM |
Iqvia (NYSE:IQV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Iqvia (NYSE:IQV) Income Statement, Balance Sheet and Cash Flow Statement
Iqvia (NYSE IQV) Stock Chart for Monday, April, 23, 2018
Loading chart…
